These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15465335)

  • 1. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units.
    Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Nagata T; Hirokawa Y; Nagahara T
    Bioorg Med Chem; 2004 Nov; 12(21):5579-86. PubMed ID: 15465335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element.
    Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Suzuki M; Shimada T; Watanabe K; Hirokawa Y; Furugori T; Nagahara T
    J Med Chem; 2004 Oct; 47(21):5167-82. PubMed ID: 15456260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
    J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
    Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
    J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 10. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
    J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor.
    Mochizuki A; Nakamoto Y; Naito H; Uoto K; Ohta T
    Bioorg Med Chem Lett; 2008 Jan; 18(2):782-7. PubMed ID: 18039572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
    Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
    Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
    Nutescu EA; Pater K
    IDrugs; 2006 Dec; 9(12):854-65. PubMed ID: 17139573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
    Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.